brent-castillo
Uploaded by
35 SLIDES
488 VIEWS
350LIKES

Analysis of Primary End Points in Cardiovascular Studies: Insights from Major Trials

DESCRIPTION

This document provides a comprehensive analysis of primary efficacy end points in major cardiovascular trials including PLATO, TRACER, CHARISMA, and TRILOGY-ACS. It focuses on critical outcomes such as cardiovascular death, myocardial infarction (MI), stroke, and hospitalization due to ischemia or urgent revascularization. Additionally, it explores trends in major bleeding events associated with various anticoagulant treatments, including bivalirudin and rivaroxaban, and highlights the importance of understanding these outcomes in optimizing patient care and treatment strategies.

1 / 35

Download Presentation

Analysis of Primary End Points in Cardiovascular Studies: Insights from Major Trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Learning Objectives

  2. PLATO Primary Efficacy End PointCV Death, MI, or Stroke

  3. TRACER Primary End PointComposite of CV Death, MI, Stroke, Hospitalization for Ischemia, Urgent Revascularization

  4. CHARISMA

  5. Bleeding Trends in PCI

  6. Major Bleeding at Access SitesPooled Analysis of Bivalirudin Studies

  7. TRITON-TIMI 38

  8. ATLAS ACS 2—TIMI 51Mortality Benefit With Very-Low-Dose Rivaroxaban in STEMI Patients

  9. TRILOGY-ACSPrimary Efficacy End Point to 30 Months (Age < 75 years)

  10. TRILOGY-ACS Subgroup Analysis in Patients With Non-STEMI ACS

  11. ACUITY Intraprocedural Thrombotic Events (IPTE*)

  12. Intraprocedural Stent Thrombosis During PCI

  13. EUROMAXStent Thrombosis With Bivalirudin Treatment

  14. RAPIDPatients With Residual Reactivity Over Time

  15. CHAMPION PLATFORM

  16. CHAMPION PCI

  17. CHAMPION PHOENIX Primary Efficacy Outcomes at 48 Hours, MITT

  18. Third Universal Definition of MI

  19. Abbreviations

  20. Abbreviations (cont)

  21. References

  22. References (cont)

  23. References (cont)

  24. References (cont)

  25. References (cont)

  26. References (cont)

  27. References (cont)

  28. References (cont)

More Related